Home › Kanser sa Baga › Pennsylvania › Pittsburgh
Pag-aaral pangklinika para sa Kanser sa Baga sa Pittsburgh, PA
Isang pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Pittsburgh. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Nagre-recruitPhase 3
- Bryn Mawr Hospital, Bryn Mawr · 11 mi ang layo
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- at 11 pa
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Nagre-recruitPhase 3
- Bryn Mawr Hospital, Bryn Mawr · 11 mi ang layo
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Nagre-recruit
- UPMC Hillman Cancer Center, Pittsburgh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Nagre-recruitPhase 3
- UPMC Hillman Cancer Center, Pittsburgh
- Bryn Mawr Hospital, Bryn Mawr · 11 mi ang layo
- UPMC Hillman Cancer Center - Monroeville, Monroeville · 11 mi ang layo
- at 1 pa
A Registry for People With Lung Cancer
Nagre-recruitObservasyonal na pag-aaral
- ALLEGHENY HEALTH NETWORK (Data Collection Only), Pittsburgh
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Nagre-recruitPhase 2
- Research Site, Pittsburgh
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Nagre-recruitPhase 2/3
- West Penn Allegheny Health, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- Allegheny Health Network, Pittsburgh
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Nagre-recruitPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Allegheny Cancer Center, Pittsburgh
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Nagre-recruitPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Nagre-recruitPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Nagre-recruitPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Nagre-recruitPhase 2
- Allegheny General Hospital, Natrona Heights · 19 mi ang layo
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Nagre-recruitPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- at 11 pa
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- at 9 pa
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Nagre-recruitObservasyonal na pag-aaral
- Allegheny Health Network, Pittsburgh
Detection of Genetic Markers of Lung Cancer
Nagre-recruitObservasyonal na pag-aaral
- Hillman Cancer Center, Pittsburgh
Pag-aaral para sa Kanser sa Baga sa ibang lungsod
- Houston, TX78 pag-aaral
- Boston, MA62 pag-aaral
- New York City, NY60 pag-aaral
- Los Angeles, CA45 pag-aaral
- Arlington, VA41 pag-aaral
- Washington, DC41 pag-aaral
- Chicago, IL41 pag-aaral
- Nashville, TN40 pag-aaral
- Baltimore, MD40 pag-aaral
- St. Louis, MO39 pag-aaral
- Columbus, OH37 pag-aaral
- Philadelphia, PA36 pag-aaral
Iba pang pag-aaral sa Pittsburgh
- Non-Small Cell Lung Cancer48 pag-aaral
- Kanser (lahat ng uri)41 pag-aaral
- Kanser sa Suso39 pag-aaral
- Colorectal Cancer32 pag-aaral
- Metastatic Cancer31 pag-aaral
- Melanoma31 pag-aaral
- Kanser sa Ovary30 pag-aaral
- Kanser ng Endometrium23 pag-aaral
- Kanser sa Prostate23 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg22 pag-aaral
- Stroke22 pag-aaral
- Depression22 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.